5-lipoxygenase as an endogenous modulator of amyloid ß formation in vivo.
AuthorsChu J, Praticò D,
JournalAnn Neurol
PubMed ID21280074
'The 5-lipoxygenase (5-LO) enzymatic pathway is widely distributed within the central nervous system, and is upregulated in Alzheimer''s disease. However, the mechanism whereby it may influence the disease pathogenesis remains elusive. We evaluated the molecular mechanism by which 5-LO regulates amyloid ß (Aß) formation in vitro and in vivo by ... More
Trans-dominant negative effects of pathogenic PSEN1 mutations on ?-secretase activity and Aß production.
AuthorsHeilig EA, Gutti U, Tai T, Shen J, Kelleher RJ,
Journal
PubMed ID23843529
Mutations in the PSEN1 gene encoding Presenilin-1 (PS1) are the predominant cause of familial Alzheimer's disease (FAD), but the underlying mechanisms remain unresolved. To reconcile the dominant action of pathogenic PSEN1 mutations with evidence that they confer a loss of mutant protein function, we tested the hypothesis that PSEN1 mutations ... More
Involvement of 5-lipoxygenase in the corticosteroid-dependent amyloid beta formation: in vitro and in vivo evidence.
AuthorsPuccio S, Chu J, Praticò D,
JournalPLoS One
PubMed ID21253592
Numerous studies show that high circulating level of glucocorticosteroids is a biochemical characteristic of Alzheimer's disease (AD). These stress hormones can increase the amount of AD-like pathology in animal models of the disease. Since they also up-regulate the 5-Lipoxygenase (5-LO), an enzyme which modulates amyloid beta (Aß) formation, in the ... More